Inhibition of caspase activity with the pan-caspase inhibitor Z-VAD-FMK completely mitigated the super-additive cytotoxicity effect and the induction of sub-G1 cells caused by CuET with trametinib in the BRAF WT melanoma cell lines (Fig. 3A and B). The gene discussed is BRAF; the disease is melanoma.